Supernus Pharma (SUPN) Misses Q4 EPS by 48c, provides guidance

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.07), $0.48 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $211.6 million versus the consensus estimate of $195.48 million.

GUIDANCE:

Supernus Pharma sees FY2026 revenue of $840-870 million, versus the consensus of $861.2 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Clean Air Metals closes C$6.2M private placement tied to Springbok deal
• Battery X Metals plans $1M private placement, superseding prior offering